Solara Active Pharma Sciences Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 13, 2025, 8:27 pm

Competitors of Solara Active Pharma Sciences Ltd

All Competitor Stocks of Solara Active Pharma Sciences Ltd

Quarterly Result

Last Updated: May 31, 2025, 7:44 am

Below is a detailed analysis of the quarterly data for Solara Active Pharma Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 273.01 Cr.. The value appears to be declining and may need further review. It has decreased from 300.31 Cr. (Dec 2024) to 273.01 Cr., marking a decrease of 27.30 Cr..
• For Expenses, as of Mar 2025, the value is 227.64 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 242.63 Cr. (Dec 2024) to 227.64 Cr., marking a decrease of 14.99 Cr..
• For Operating Profit, as of Mar 2025, the value is 45.37 Cr.. The value appears to be declining and may need further review. It has decreased from 57.68 Cr. (Dec 2024) to 45.37 Cr., marking a decrease of 12.31 Cr..
• For OPM %, as of Mar 2025, the value is 16.62%. The value appears to be declining and may need further review. It has decreased from 19.21% (Dec 2024) to 16.62%, marking a decrease of 2.59%.
• For Other Income, as of Mar 2025, the value is 5.95 Cr.. The value appears strong and on an upward trend. It has increased from 1.49 Cr. (Dec 2024) to 5.95 Cr., marking an increase of 4.46 Cr..
• For Interest, as of Mar 2025, the value is 29.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 26.54 Cr. (Dec 2024) to 29.12 Cr., marking an increase of 2.58 Cr..
• For Depreciation, as of Mar 2025, the value is 24.30 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 24.54 Cr. (Dec 2024) to 24.30 Cr., marking a decrease of 0.24 Cr..
• For Profit before tax, as of Mar 2025, the value is -2.10 Cr.. The value appears to be declining and may need further review. It has decreased from 8.09 Cr. (Dec 2024) to -2.10 Cr., marking a decrease of 10.19 Cr..
• For Tax %, as of Mar 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00%.
• For Net Profit, as of Mar 2025, the value is -2.10 Cr.. The value appears to be declining and may need further review. It has decreased from 8.09 Cr. (Dec 2024) to -2.10 Cr., marking a decrease of 10.19 Cr..
• For EPS in Rs, as of Mar 2025, the value is -0.58. The value appears to be declining and may need further review. It has decreased from 2.24 (Dec 2024) to -0.58, marking a decrease of 2.82.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: March 7, 2025, 6:48 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 12, 2025, 2:41 pm

Below is a detailed analysis of the balance sheet data for Solara Active Pharma Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 40.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2024) to 40.00 Cr., marking an increase of 4.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,054.00 Cr.. The value appears strong and on an upward trend. It has increased from 898.00 Cr. (Mar 2024) to 1,054.00 Cr., marking an increase of 156.00 Cr..
• For Borrowings, as of Mar 2025, the value is 796.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1,012.00 Cr. (Mar 2024) to 796.00 Cr., marking a decrease of 216.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 342.00 Cr.. The value appears to be improving (decreasing). It has decreased from 406.00 Cr. (Mar 2024) to 342.00 Cr., marking a decrease of 64.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,232.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,351.00 Cr. (Mar 2024) to 2,232.00 Cr., marking a decrease of 119.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,193.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,268.00 Cr. (Mar 2024) to 1,193.00 Cr., marking a decrease of 75.00 Cr..
• For CWIP, as of Mar 2025, the value is 280.00 Cr.. The value appears strong and on an upward trend. It has increased from 256.00 Cr. (Mar 2024) to 280.00 Cr., marking an increase of 24.00 Cr..
• For Investments, as of Mar 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.00 Cr..
• For Other Assets, as of Mar 2025, the value is 757.00 Cr.. The value appears to be declining and may need further review. It has decreased from 825.00 Cr. (Mar 2024) to 757.00 Cr., marking a decrease of 68.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,232.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,351.00 Cr. (Mar 2024) to 2,232.00 Cr., marking a decrease of 119.00 Cr..

Notably, the Reserves (1,054.00 Cr.) exceed the Borrowings (796.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Solara Active Pharma Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 24, the value is -157.62. This value is below the healthy minimum of 5. It has decreased from -6.16 (Mar 23) to -157.62, marking a decrease of 151.46.
• For Diluted EPS (Rs.), as of Mar 24, the value is -157.62. This value is below the healthy minimum of 5. It has decreased from -6.16 (Mar 23) to -157.62, marking a decrease of 151.46.
• For Cash EPS (Rs.), as of Mar 24, the value is -128.79. This value is below the healthy minimum of 3. It has decreased from 24.70 (Mar 23) to -128.79, marking a decrease of 153.49.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 260.16. It has decreased from 417.35 (Mar 23) to 260.16, marking a decrease of 157.19.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 260.16. It has decreased from 417.35 (Mar 23) to 260.16, marking a decrease of 157.19.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 358.03. It has decreased from 401.06 (Mar 23) to 358.03, marking a decrease of 43.03.
• For PBDIT / Share (Rs.), as of Mar 24, the value is -24.95. This value is below the healthy minimum of 2. It has decreased from 43.45 (Mar 23) to -24.95, marking a decrease of 68.40.
• For PBIT / Share (Rs.), as of Mar 24, the value is -53.65. This value is below the healthy minimum of 0. It has decreased from 12.57 (Mar 23) to -53.65, marking a decrease of 66.22.
• For PBT / Share (Rs.), as of Mar 24, the value is -135.67. This value is below the healthy minimum of 0. It has decreased from -12.45 (Mar 23) to -135.67, marking a decrease of 123.22.
• For Net Profit / Share (Rs.), as of Mar 24, the value is -157.49. This value is below the healthy minimum of 2. It has decreased from -6.18 (Mar 23) to -157.49, marking a decrease of 151.31.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -157.61. This value is below the healthy minimum of 2. It has decreased from -6.16 (Mar 23) to -157.61, marking a decrease of 151.45.
• For PBDIT Margin (%), as of Mar 24, the value is -6.96. This value is below the healthy minimum of 10. It has decreased from 10.83 (Mar 23) to -6.96, marking a decrease of 17.79.
• For PBIT Margin (%), as of Mar 24, the value is -14.98. This value is below the healthy minimum of 10. It has decreased from 3.13 (Mar 23) to -14.98, marking a decrease of 18.11.
• For PBT Margin (%), as of Mar 24, the value is -37.89. This value is below the healthy minimum of 10. It has decreased from -3.10 (Mar 23) to -37.89, marking a decrease of 34.79.
• For Net Profit Margin (%), as of Mar 24, the value is -43.98. This value is below the healthy minimum of 5. It has decreased from -1.54 (Mar 23) to -43.98, marking a decrease of 42.44.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is -44.02. This value is below the healthy minimum of 8. It has decreased from -1.53 (Mar 23) to -44.02, marking a decrease of 42.49.
• For Return on Networth / Equity (%), as of Mar 24, the value is -60.75. This value is below the healthy minimum of 15. It has decreased from -1.47 (Mar 23) to -60.75, marking a decrease of 59.28.
• For Return on Capital Employeed (%), as of Mar 24, the value is -17.42. This value is below the healthy minimum of 10. It has decreased from 2.51 (Mar 23) to -17.42, marking a decrease of 19.93.
• For Return On Assets (%), as of Mar 24, the value is -24.13. This value is below the healthy minimum of 5. It has decreased from -0.76 (Mar 23) to -24.13, marking a decrease of 23.37.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.11. This value is below the healthy minimum of 0.2. It has decreased from 0.15 (Mar 23) to 0.11, marking a decrease of 0.04.
• For Total Debt / Equity (X), as of Mar 24, the value is 1.07. This value exceeds the healthy maximum of 1. It has increased from 0.66 (Mar 23) to 1.07, marking an increase of 0.41.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.49. There is no change compared to the previous period (Mar 23) which recorded 0.49.
• For Current Ratio (X), as of Mar 24, the value is 0.64. This value is below the healthy minimum of 1.5. It has decreased from 1.08 (Mar 23) to 0.64, marking a decrease of 0.44.
• For Quick Ratio (X), as of Mar 24, the value is 0.35. This value is below the healthy minimum of 1. It has decreased from 0.57 (Mar 23) to 0.35, marking a decrease of 0.22.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.66. This value is below the healthy minimum of 4. It has increased from 1.37 (Mar 23) to 1.66, marking an increase of 0.29.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 24, the value is -0.85. This value is below the healthy minimum of 3. It has decreased from 1.74 (Mar 23) to -0.85, marking a decrease of 2.59.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is -2.58. This value is below the healthy minimum of 3. It has decreased from 0.75 (Mar 23) to -2.58, marking a decrease of 3.33.
• For Enterprise Value (Cr.), as of Mar 24, the value is 2,334.27. It has increased from 2,176.74 (Mar 23) to 2,334.27, marking an increase of 157.53.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.81. This value is within the healthy range. It has increased from 1.51 (Mar 23) to 1.81, marking an increase of 0.30.
• For EV / EBITDA (X), as of Mar 24, the value is -25.99. This value is below the healthy minimum of 5. It has decreased from 13.92 (Mar 23) to -25.99, marking a decrease of 39.91.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.04. This value is within the healthy range. It has increased from 0.81 (Mar 23) to 1.04, marking an increase of 0.23.
• For Retention Ratios (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Price / BV (X), as of Mar 24, the value is 1.44. This value is within the healthy range. It has increased from 0.78 (Mar 23) to 1.44, marking an increase of 0.66.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.04. This value is within the healthy range. It has increased from 0.81 (Mar 23) to 1.04, marking an increase of 0.23.
• For EarningsYield, as of Mar 24, the value is -0.42. This value is below the healthy minimum of 5. It has decreased from -0.01 (Mar 23) to -0.42, marking a decrease of 0.41.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness